Catalogue

Background
Glypican-3 encodes a putative extracellular proteoglycan that is inferred to play an important role in growth control in embryonic mesodermal tissues in which it is selectively expressed. It appears to form a complex with insulin-like growth factor and hence modulate IGF2 action. Glypican-3 is the human homolog of OCI-5, a GPI-linked proteoglycan first isolated from rat intestine. Originally identified as the molecular basis for Simpson-Golabi-Behmel syndrome (SGBS) also called Simpson dysmorphia syndrome (SDYS).

Synonyms: GPC3, GPC-3, OCI5, OCI-5, GTR2-2, MXR7

Source

Immunogen: C terminal recombinant protein (~70aa) which does not overlap with clone 1G12 epitope)

Product

Product Form: Unconjugated

Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide

Purification Method: Total IgG

Concentration: See vial for concentration

Applications
Antibody can be used for immunohistochemistry on paraffin-embedded tissues (10 µg/ml) and Western blotting (5-10 µg/ml). Optimal concentration should be evaluated by serial dilutions.

Functional Analysis: Immunohistochemistry

Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Product Stability: See expiration date on vial

Shipping Conditions: Ship at ambient temperature, freeze upon arrival

Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio​ accepts no liability for any inaccuracies or omissions in this information.

References
1. Lai, J.P., et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008, 47, 1211-1222. 2. Zynger, D.L., et al. Expression of glypican 3 in ovarian and extragonadal germ cell tumors. Am. J. Clin. Pathol. 2008, 130, 224-230. 3. Anatelli, F., et al. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am. J. Clin. Pathol. 2008, 130, 219-223. 4. Yamanaka, K., et al. Immunohistochemical study of glypican 3 in thyroid cancer. Oncology 2007, 73, 389-394. 5. Filmus, J., et al. Glypicans. Genome Biol. 2008, 9, 224. 6. Baumhoer, D., et al. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples. Am. J. Clin. Pathol. 2008, 129, 899-906. 7. Capurro, M.I., et al. Glypican-3 inhibits Hedgehog signaling during development by competing with patched for Hedgehog binding. Dev. Cell 2008, 14, 700-711. 8. Motomura, Y., et al. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice. Int. J. Oncol. 2008, 32, 985-990. 9. Cheng, W., et al. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29, 1319-1326.

Protein Reference(s)

Database Name: UniProt

Accession Number: P51654

Species Accession: Human

Safety Datasheet(s) for this product: